2026
Hooda N, Suh M , Bylsma LC, Kelsh M. A systematic literature review of the association between dose reduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and survival in patients with HR-positive breast cancer (BC). Poster 1882eP, European Society for Medical Oncology (ESMO) Congress 2026, Madrid, Spain, October 23-27, 2026.
View Abstract
Publication: Abstracts and Presentations
Suh M , Jiang X, Movva N, Pastula ST, Reichert H. The disease burden of RSV and bronchiolitis among United States infants in 2019-2023. Poster B-089, Poster Session B, International Society for Pharmacoepidemiology (ISPE) 42nd Annual Meeting, Milan, Italy, September 1, 2026.
View Abstract
Publication: Abstracts and Presentations
Bylsma L, Suh M , Movva N, Pastula S, Gauthier J , Itlzer R, Harrington A. 2026. Protocol for systematic literature review of efficacy/effectiveness, safety, and long-term impact of supportive care treatment in adults with primary mitochondrial diseases. PROSPERO 2026:CRD42026143005. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261434005 .
View Abstract
Publication: Protocol Registrations
Perreault L, Rasouli N, Sanogo F, Movva N, Bylsma L, Suh M , Reichert H, Donsmark M, Girguis M, Frankenfeld C. A meta-analysis of persistence and adherence to glucagon-like peptide 1-based treatments among patients with type 2 diabetes in the United States. Abstract/Poster 1691-P, American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, June 7, 2026.
View Abstract
Publication: Abstracts and Presentations
Lea IA , Rivera B, Rogers S, Borghoff SJ . 2026. Assessment of the carcinogenic potential of automotive gasoline in humans based on mechanistic evidence. Curr Res Toxicol 10:100284; doi: 10.1016/j.crtox.2026.100284 . PMID: 41755915.
View Abstract
Publication: Manuscripts
2025
Movva N, Bylsma L, Suh M , Kelsh M, Van Valkenburgh H, Zaha R. 2025. Systematic literature review of bioavailability of characteristics, clinical presentations, and outcomes among women with pregnancies affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) and/or have anti-HPA-1a antibodies with no history of FNAIT. PROSPERO 2025:CRD420251153257. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251153257 .
View Abstract
Publication: Protocol Registrations
Suh M , Movva N, Izikson R, La Via W, Pastula S, Machado MAA, Shin T, Rizzo C. The burden of respiratory syncytial virus among young children in the United States is not well-documented across settings: A systematic literature review. Abstract P2192, IDWeek, Atlanta GA, October 2025.
View Abstract
Publication: Abstracts and Presentations
Movva N, Girguis M, Bylsma L, Saleem N, Grasic K, Suh M , Pastula S, Frankenfeld C. 2025. Systematic literature review of glucagon-like peptide 1 (GLP-1) receptor agonist use among type 2 diabetes in the United States. PROSPERO 2025:CRD4202564618. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025646418 .
View Abstract
Publication: Protocol Registrations
2024
Suh M, Mittal L, Brorby G , Pastula S, Vincent M, Proctor D. Epidemiology is critical in advancing cumulative impact assessment (CIA) research: A pilot study in San Antonio, Texas. International Society of Exposure Science, Montreal, Canada, October 2024.
View Abstract
Publication: Abstracts and Presentations
East A, Klaren W , Covington T, Rish W. Exploring biomarker-based methods to incorporate non-chemical stressor exposures into cumulative assessments for potentially vulnerable population groups. International Society of Exposure Science, Montreal, Canada, October 2024.
View Abstract